Nevertheless our findings suggest that AR expression does not predict the efficacy of first-line endocrine treatment (mainly based on aromatase inhibitors in our study) in ER- or PgR-positive advanced BC, both in term of TTP and PD as best response. The gene discussed is AR; the disease is breast cancer.